| November 29, 2012 | ISSUE NUMBER 278 VOL 8 |
Confirm your PharmExec Direct e-newsletter subscription
We noticed you haven’t opened your PharmExec Direct e-newsletter in quite a while. While we don’t want to lose you as a valuable reader, we understand that preferences do change. If you would like to continue receiving the PharmExec Direct e-newsletter, please take a moment to confirm your subscription by clicking here.
If you have just been having trouble receiving your PharmExec Direct e-newsletter, be sure to add our new email address pharmexec@advanstarpharmex.com to your address book or safe sender list to ensure delivery.
Kind regards,
Pharmaceutical Executive Staff |
Healthcare Reform
Pharma to Gain from New Health Insurance Proposals
A key change in rules to implement the Affordable Care Act (ACA) is regarded as a big win for pharma, as some 20 million Americans are expected to enroll in plans sold through exchanges, greatly expanding the market for prescription drugs. Jill Wechsler reports ...Read more
Advertisement
Measurement of case quality in pharmacovigilance is a relatively new development. Until pharmaceutical companies began outsourcing their case processing operations, the only measure of effectiveness of their internal operations was compliance with regulatory reporting timelines. Now that these operations are performed by vendors, over the last two years vendor management organizations within pharmaceutical companies and Health Authorities have come up with a way to measure the “quality” of Adverse Event (AE) cases. This paper captures our experience and learning in defining and using  Case Quality Metrics while working with large and small pharmaceutical companies.
Contact Email:ask@sciformix.com |
Pipeline
Pharm Exec's 2013 Pipeline Report: An End to the Gloom?
Is the "lost decade" of declining pipeline productivity finally over? Our annual survey of analyst assessments of the state of drug development suggests so, with subtle shards of sunlight beginning to penetrate the gloom cast by the historic loss of exclusivity on more than $80 billion of blockbuster medicines since 2009...Read More
Funding
PCORI Opens its Pocketbook
The Patient-Centered Outcomes Research Institute (PCORI) has proposed grants totaling $12 million for up to 14 contracts for studies aimed at improving upon existing research methodologies to demonstrate clinical effectiveness
...Read more
Drug Launch
Why Do So Many New Drugs End Up as Launch Failures?
Pharm Exec's new iPad edition eBook, Global Launch in a Post-blockbuster Era, is available for download now
...Read more |
|
|
 // Sanofi appointed Dr Gary Nabel, Senior VP, Chief Scientific Officer and Deputy to the President for Global R&D. Dr Nabel will be based in Cambridge, MA. // NovaMedica appointed Fabrice Egros as its Chief Operating Officer. The company was formed in 2011 as part of a $760m collaboration between the Russian technology investment fund Rusnano and US healthcare venture fund Domain Associates. // Dr Eugene Washington was appointed to the Board of directors at Johnson & Johnson.// Ampio Pharmaceuticals, Inc. (Greewood Village, CO) announced the appointment of Josh Disbrow as Chief Operating Officer, effective December 15.
|
|
|
|
|
|
 |
|
 |
|
 |
|
 |
|
 |
Compared with 2011, has your company attended more or fewer conferences in 2012?
|
|
|
|
